Pharmaceuticals
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease
* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates to meet high unmet medical needs in Parkinson's disease SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology...
2023-02-20 22:00
3299
Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
CHENGDU, China, Feb. 20, 2023 /PRNewswire/ -- Recently, with the support of the National Key R&D Program ofChina, following the clinical trial approval for Recombinant Variant COVID-19 Vaccine (Sf9 cell) approved by NMPA, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred to as "WestVa...
2023-02-20 12:43
4737
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
2023-02-20 12:29
2960
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
2023-02-20 09:38
2880
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): * Primary endpoint met: Sensitivi...
2023-02-20 07:10
3460
Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer
SINGAPORE, Feb. 17, 2023 /PRNewswire/ -- February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/meta...
2023-02-17 23:13
9657
Farrer Park Hospital launches clinical collaboration with ARC Hospitals
SINGAPORE, Feb. 17, 2023 /PRNewswire/ -- Farrer Park Hospital (FPH) has launched a clinical collaboration with Allegiant Regional Care (ARC) Hospitals to promote continuing medical education among specialists and physicians. The collaboration was officially launched at a joint surgical conference...
2023-02-17 20:38
5380
/C O R R E C T I O N -- DoctorOnCall/
In the news release, NCSM & DoctorOnCall Join Forces to Promote Free COVID-19 Vaccination and Booster Doses (Including On-site and House-to-House), issued 12-Feb-2023 by DoctorOnCall over PR Newswire, we are advised by the company that the 7th paragraph, 1st sentence, should read "For more informa...
2023-02-17 08:00
5737
Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders
JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), aChina-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of$0.05 per ordinary share, payable i...
2023-02-17 05:30
4361
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patients * YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 16, 2023 /PRNewswire/ -- Independen...
2023-02-17 03:00
3193
Dalton Announces Major Expansion in Commercial Sterile Manufacturing Capacity
TORONTO, Feb. 17, 2023 /PRNewswire/ -- Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility t...
2023-02-17 01:37
5454
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies,announced the ...
2023-02-16 20:36
7895
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...
2023-02-16 17:10
4406
Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck
HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Me...
2023-02-16 15:00
2355
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committ...
2023-02-16 14:00
4165
111, Inc. Hosts Hua Medicine Launches First Official Flagship Store
SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr.Yu Gang, Co-founder and Executive...
2023-02-16 13:33
2905
Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial
YANTAI, China, Feb. 16, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA2101, an investigational anti-IL-4Rα antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innovative biological prod...
2023-02-16 08:15
5244
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology ...
2023-02-16 08:00
5109
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/ -- Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovativ...
2023-02-15 21:30
4679
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved in the U.S. - * HLX02 (trastuzumab for injection, trade name in China: HANQUYOU; trade name inEurope: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®) has been approved in more than 3...
2023-02-15 16:49
4606
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
45088
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
35039
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
20652
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
18247
